Montelukast for Early Life Wheezing

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Lung DiseasesAsthma
Interventions
DRUG

Montelukast

Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.

DRUG

Placebo

Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.

Trial Locations (1)

01650

University of Massachusetts/UMass Memorial, Worcester

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Massachusetts, Worcester

OTHER

NCT00115297 - Montelukast for Early Life Wheezing | Biotech Hunter | Biotech Hunter